The UK and US have agreed to a key trade agreement that will keep no tariffs on British medicine exports being sold in the American market.
Agreement Details of the Accord
In exchange for the tariff guarantee, the UK has pledged to boost expenditure on pharmaceuticals through the NHS. This commitment ensures that tariffs on these key goods will be held at zero for a timeframe of the next three years.
This agreement is in response to recent threats to hike duties on patented drug imports, with increases floated as high as 100%.
"This arrangement with the UK bolsters the global environment for innovative medicines and introduces much-needed fairness to transatlantic medicine commerce," a release declared.
Economic Importance
Drugs are one of the the United Kingdom's largest exports to the United States, which is easily the largest destination for major companies like GSK and AstraZeneca.
Statistics show that in the year prior to last September, the UK sold drugs valued at £11.1bn to the US. This figure represented a significant portion of total UK exports in that period.
"This agreement protects jobs, boosts capital expenditure and sets the stage for the UK to establish itself as a worldwide center for life sciences," a minister stated.
Detailed NHS Changes
The deal includes several notable pledges from the United Kingdom:
- Higher Cost Ceiling: The UK will increase the price threshold at which it considers new therapies to be too expensive by a quarter.
- Increased NHS Spending: There is a goal to raise total NHS spending on medicines from 0.3% of the national economy to 0.6% over the next decade.
- Payback Limit: The percentage pharmaceutical firms must pay back to the NHS to stay within budget will be capped at fifteen percent. Last year, refunds exceeded 20%.
Industry Background
This agreement comes amid a protracted row between the drug companies and the UK government over medicine costs and regulatory access.
These tensions were heightened by arguments that American patients were charged several times more for the same drugs than consumers in the UK and Europe.
Recently, several major pharmaceutical investments in the UK have been paused or cancelled, while substantial investments have been pledged toward American operations.
The Science Minister publicly accepted that the NHS must increase expenditure on treatments, noting that its spending on drugs had declined as a share of its resources over the past decade.
